Celiac disease: A model autoimmune disease with gene therapy applications

M. Londei, S. Quaratino, L. Maiuri

Research output: Contribution to journalArticle

Abstract

Gene therapy (GT) is still at the 'experimental' stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality.

Original languageEnglish
Pages (from-to)835-843
Number of pages9
JournalGene Therapy
Volume10
Issue number10
DOIs
Publication statusPublished - May 2003

Fingerprint

Celiac Disease
Genetic Therapy
Autoimmune Diseases
Therapeutic Uses
Autoimmunity
Disease Progression
Therapeutics
Animal Models

ASJC Scopus subject areas

  • Genetics

Cite this

Celiac disease : A model autoimmune disease with gene therapy applications. / Londei, M.; Quaratino, S.; Maiuri, L.

In: Gene Therapy, Vol. 10, No. 10, 05.2003, p. 835-843.

Research output: Contribution to journalArticle

Londei, M. ; Quaratino, S. ; Maiuri, L. / Celiac disease : A model autoimmune disease with gene therapy applications. In: Gene Therapy. 2003 ; Vol. 10, No. 10. pp. 835-843.
@article{14d22e8d4c9b4a55af49c0ccc7e16efa,
title = "Celiac disease: A model autoimmune disease with gene therapy applications",
abstract = "Gene therapy (GT) is still at the 'experimental' stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality.",
author = "M. Londei and S. Quaratino and L. Maiuri",
year = "2003",
month = "5",
doi = "10.1038/sj.gt.3302041",
language = "English",
volume = "10",
pages = "835--843",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Celiac disease

T2 - A model autoimmune disease with gene therapy applications

AU - Londei, M.

AU - Quaratino, S.

AU - Maiuri, L.

PY - 2003/5

Y1 - 2003/5

N2 - Gene therapy (GT) is still at the 'experimental' stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality.

AB - Gene therapy (GT) is still at the 'experimental' stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality.

UR - http://www.scopus.com/inward/record.url?scp=0037809288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037809288&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302041

DO - 10.1038/sj.gt.3302041

M3 - Article

C2 - 12732869

AN - SCOPUS:0037809288

VL - 10

SP - 835

EP - 843

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 10

ER -